All News

FDA approved roflumilast (Zoryve) cream 0.3% for plaque psoriasis in children as young as age 2, expanding the once-daily steroid-free topical indication.

A deep learning ECG model identified a high-risk group with a 7.0% annual sudden cardiac death rate in a new study.

FDA approved risankizumab for children aged 6 years or older with moderate to severe plaque psoriasis or active psoriatic arthritis.

Centanafadine XR improved adult ADHD symptoms in a phase 3b trial of patients with comorbid generalized or social anxiety disorder.

SLEEP 2026: Ashesha Mechineni, MD, discusses what the emerging pharmacotherapy pipeline means for clinicians.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Survey finds 18 million women 45–64 overdue for cancer screening, led by colorectal gaps—bundled reminders could

Sairam Parthasarathy, MD, discusses late-breaking research he presented at SLEEP 2026 that showed hypoglossal nerve stimulation outperformed CPAP to improve OSA.

Patients with OSA who cannot tolerate CPAP may benefit from discussions about oral appliances, HNS, and other treatment options. Sairam Parthasarathy, MD, dives deeper.

Social, behavioral, and environmental factors improved risk prediction beyond genetic scores for 6 common diseases in All of Us data.

The CRL cites deficiencies at a third-party manufacturing facility, with no efficacy or clinical safety deficiencies identified.

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

Laura B. Herpel, MD, reviews REFRESH trial data on once-nightly oxybate in narcolepsy, focusing on daytime function, stimulant reduction, and mental health.

FDA approved teplizumab to help preserve insulin production in children with recent-onset stage 3 type 1 diabetes.

Patil reviews 3 new AASM guidelines at SLEEP 2026 covering updated CSA treatment, first-ever inpatient OSA guidance, and chronic insomnia therapy hierarchy.

Andrew Ho, MD, reviews single-center data showing GLP-1 coverage barriers reshaped OSA referral patterns, with symptom documentation absent in most cases.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.